Not the first firm product to take a run at Oncotype Dx....probably not the last....interesting though.
Nanostring makes a big deal out of the categories low risk, intermediate risk and high risk. In reality, OncoType results come in the form of a raw number score...not a range. A score of 25 on Oncotype is considered intermediate but it is really the point where chemo should strongly be considered. Below 25, statistically, is low. Either way, most women in intermediate and high are recommended chemo anyway. Low risk is the most useful category...ie you don't need chemo. Oncotype produced more low risk results than Nanostring in their own studies.